Summary

Eligibility
for people ages 18-70 (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around
Principal Investigator
by Xiao-Tang Kong

Description

Summary

This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.

Official Title

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients With Methylated MGMT Promoter Glioblastoma

Details

Keywords

Glioblastoma, Gliosarcoma, Temozolomide, Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, radiation therapy, temozolomide, radiation therapy, temozolomide, lomustine

Eligibility

Locations

Lead Scientist at UC Irvine

  • Xiao-Tang Kong
    Health Sciences Professor, Neurology, School of Medicine. Authored (or co-authored) 13 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
NRG Oncology
ID
NCT05095376
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 306 study participants
Last Updated